Mason-Dixon National Poll of 1,000 Adults Commissioned by Peppies.com and Released Monday Ahead of the PCAC Vote Shows 52% of Americans Favor Legal Peptide Compounding Access Through a Licensed US Pharmacy With a Doctor's Prescription, 3% Are Opposed, and 45% Are Unsure — a 19-to-1 Support Ratio Among Those With an Opinion; The Same Poll Documented 60% Support for a US Healthcare System That Prioritizes Preventing Illness Versus 19% for Treating Existing Illness
A Mason-Dixon Polling & Strategy national telephone survey of 1,000 adults commissioned by peptide-education resource Peppies.com released Monday July 20, 2026 documented broad American support for legal peptide compounding access. Field dates: July 13-16, 2026. Sample drawn from a nationwide voter-registration list including landlines and mobile phones, with quotas by state to reflect the adult population. Key finding: 52% of respondents favor being able to obtain peptides through a licensed US pharmacy with a doctor's prescription, 3% oppose, and 45% are unsure. Among the 55% of adults expressing an opinion, adult access is favored by a 19-to-1 ratio. Secondary findings: 60% say the US healthcare system should prioritize preventing illness versus 19% who say it should prioritize treating existing illness, framing the peptide-access debate in the broader public-health prevention conversation. The poll landed days before the FDA Pharmacy Compounding Advisory Committee (PCAC) opens the July 23-24 vote on seven peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) at White Oak. The Peppies.com commissioning framing casts the current situation as 'peptide roulette' — patients buying gray-market products of unknown quality because licensed compounding pathways are closed.